Loading organizations...
Key people at JVC Investment Partners.
JVC Investment Partners was founded in 2000 by David N Jonas (Founder, President and CEO).
JVC Investment Partners is a private investment firm deploying its own capital into businesses across various sectors and growth stages. The firm prioritizes investing in the people behind a venture, focusing on their vision and potential. This approach enables them to support a diverse portfolio through strategic partnerships and financial backing, extending beyond strict industry verticals.
Founded in 2000 by David N. Jonas, the firm emerged from his distinguished entrepreneurial career. Mr. Jonas previously built PharMEDium Healthcare Corporation into a leading outsourced sterile compounding pharmacy services provider, ultimately leading to its multi-billion dollar acquisition. His significant operational experience and personal capital then became dedicated to supporting other emerging businesses.
JVC Investment Partners partners with entrepreneurs and innovators seeking capital and experienced guidance to scale their operations. The firm's long-term vision centers on fostering the growth of promising ventures by aligning with strong leadership and innovative concepts, empowering them to achieve their full market potential with dedicated support.
JVC Investment Partners was founded in 2000 by David N Jonas (Founder, President and CEO).
Key people at JVC Investment Partners.
JVC Investment Partners has 3 tracked investments across 3 companies. The latest tracked deal is $190.0M Series A in New Amsterdam Pharma in January 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2021 | New Amsterdam Pharma | $190.0M Series A | Ascendant BioCapital, Forbion, Jason Dinges | Founders Fund, Presight Capital, Peter Thiel, BVF Partners, GL Capital, Janus Henderson Investors, Kaiser Permanente, LSP, Medpace, Population Health Partners |
| Aug 18, 2020 | ImmPACT Bio | $18.0M Series A | — | Bukwang Pharmaceutical, Hayan Health Networks, Johnson & Johnson Innovation, Novartis, OrbiMed, RM Global Partners, Takeda Ventures |
| Oct 3, 2019 | Arcellx | $85.0M Series B | Hugo Beekman, Lewis (rusty) Williams | LG Technology Ventures, Mirae Asset Capital, Mirae Asset Venture Investment, NEA, Novo Holdings, SR ONE, Takeda Ventures |